With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is ₺2.031,89, with a 24-hour trading volume of ₺21,08B. The asset's market cap is ₺9T, after moving -1.51% in the last day.
Tokenized Novo Nordisk A/S is trading at ₺2.068,15, with a tokenized market cap of ₺165,25M and a 24-hour trading volume of ₺46,6M. The tokenized asset has moved -1.16% in the past 24 hours.